{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SC&page=4", "query": { "intervention": "SC", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 3859, "total_pages": 386, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SC&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SC&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-23T14:41:01.666Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02673567", "title": "To Assess Pharmacokinetics, Safety and Tolerability of TEV-48125 in Japanese and Caucasian Healthy Subjects After a Single Subcutaneous (SC) Administration of TEV-48125", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pharmacokinetics" ], "interventions": [ { "name": "TEV-48125 - 1", "type": "DRUG" }, { "name": "TEV-48125 - 2", "type": "DRUG" }, { "name": "TEV-48125 - 3", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 64, "start_date": "2016-03-31", "completion_date": "2017-02-10", "has_results": false, "last_update_posted_date": "2021-12-13", "last_synced_at": "2026-10-23T14:41:01.666Z", "location_count": 1, "location_summary": "Glendale, California", "locations": [ { "city": "Glendale", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02673567" }, { "nct_id": "NCT02020616", "title": "A Study of the Safety and Effectiveness of LY3053102 in Participants With Type 2 Diabetes", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "LY3053102", "type": "DRUG" }, { "name": "Exenatide ER", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 60, "start_date": "2013-12", "completion_date": "2015-02", "has_results": true, "last_update_posted_date": "2019-10-08", "last_synced_at": "2026-10-23T14:41:01.666Z", "location_count": 5, "location_summary": "Orange, California • Miami, Florida • Orlando, Florida + 2 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "New York", "state": "New York" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02020616" }, { "nct_id": "NCT07283640", "title": "A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic Leukemia", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Blinatumomab", "Revumenib", "Lymphoblastic Leukemia", "KMT2A-rearranged" ], "interventions": [ { "name": "Revumenib", "type": "DRUG" }, { "name": "Blinatumomab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2026-11-18", "completion_date": "2031-08-31", "has_results": false, "last_update_posted_date": "2026-08-12", "last_synced_at": "2026-10-23T14:41:01.666Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07283640" }, { "nct_id": "NCT04230213", "title": "A Comparative Study Between PF-06410293 and Humira® in Combination With Methotrexate in Participants With Active Rheumatoid Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "PF-06410293", "type": "DRUG" }, { "name": "adalimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 455, "start_date": "2020-01-13", "completion_date": "2021-06-22", "has_results": true, "last_update_posted_date": "2024-02-22", "last_synced_at": "2026-10-23T14:41:01.666Z", "location_count": 4, "location_summary": "Bowling Green, Kentucky • Duncansville, Pennsylvania • Dallas, Texas + 1 more", "locations": [ { "city": "Bowling Green", "state": "Kentucky" }, { "city": "Duncansville", "state": "Pennsylvania" }, { "city": "Dallas", "state": "Texas" }, { "city": "Beckley", "state": "West Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04230213" }, { "nct_id": "NCT03620162", "title": "A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pneumococcal Infections" ], "interventions": [ { "name": "Prevnar 13™", "type": "BIOLOGICAL" }, { "name": "V114", "type": "BIOLOGICAL" }, { "name": "RotaTeq™", "type": "BIOLOGICAL" }, { "name": "Pentacel™", "type": "BIOLOGICAL" }, { "name": "RECOMBIVAX HB™", "type": "BIOLOGICAL" }, { "name": "HIBERIX™", "type": "BIOLOGICAL" }, { "name": "M-M-R™ II", "type": "BIOLOGICAL" }, { "name": "VARIVAX™", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "42 Days", "maximum_age": "90 Days", "sex": "ALL", "summary": "42 Days to 90 Days" }, "enrollment_count": 900, "start_date": "2018-10-18", "completion_date": "2020-12-14", "has_results": true, "last_update_posted_date": "2023-01-17", "last_synced_at": "2026-10-23T14:41:01.666Z", "location_count": 22, "location_summary": "Birmingham, Alabama • Dothan, Alabama • Jonesboro, Arkansas + 16 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Dothan", "state": "Alabama" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03620162" }, { "nct_id": "NCT06589986", "title": "A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Moderately to Severely Active Ulcerative Colitis" ], "interventions": [ { "name": "Afimkibart", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "16 Years to 80 Years" }, "enrollment_count": 400, "start_date": "2024-09-17", "completion_date": "2031-01-30", "has_results": false, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-10-23T14:41:01.666Z", "location_count": 46, "location_summary": "Dothan, Alabama • Lancaster, California • Orange, California + 39 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Lancaster", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Brooksville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06589986" }, { "nct_id": "NCT04910568", "title": "A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Cevostamab", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 186, "start_date": "2021-07-26", "completion_date": "2028-12-21", "has_results": false, "last_update_posted_date": "2026-10-20", "last_synced_at": "2026-10-23T14:41:01.666Z", "location_count": 6, "location_summary": "Duarte, California • Irvine, California • Denver, Colorado + 3 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04910568" }, { "nct_id": "NCT01371305", "title": "STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Idiopathic Pulmonary Fibrosis (IPF)" ], "interventions": [ { "name": "BG00011", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biogen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "84 Years", "sex": "ALL", "summary": "18 Years to 84 Years" }, "enrollment_count": 41, "start_date": "2012-07-16", "completion_date": "2017-03-31", "has_results": true, "last_update_posted_date": "2020-02-28", "last_synced_at": "2026-10-23T14:41:01.666Z", "location_count": 10, "location_summary": "San Francisco, California • Atlanta, Georgia • Kansas City, Kansas + 6 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01371305" }, { "nct_id": "NCT04956302", "title": "Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Plasma Cell Myeloma", "Refractory Plasma Cell Myeloma" ], "interventions": [ { "name": "Bortezomib", "type": "DRUG" }, { "name": "Daratumumab and Hyaluronidase-fihj", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Panobinostat Lactate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Abdullah Khan", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 1, "start_date": "2021-09-27", "completion_date": "2022-06-16", "has_results": false, "last_update_posted_date": "2024-06-06", "last_synced_at": "2026-10-23T14:41:01.666Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04956302" }, { "nct_id": "NCT01087788", "title": "Certolizumab Pegol in Subjects With Adult Onset Active and Progressive Psoriatic Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Arthritis, Psoriatic" ], "interventions": [ { "name": "CZP 200 mg Q2W", "type": "BIOLOGICAL" }, { "name": "CZP 400 mg Q4W", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "UCB BIOSCIENCES GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 409, "start_date": "2010-03", "completion_date": "2015-08", "has_results": true, "last_update_posted_date": "2018-08-01", "last_synced_at": "2026-10-23T14:41:01.666Z", "location_count": 27, "location_summary": "Birmingham, Alabama • Tuscaloosa, Alabama • Peoria, Arizona + 24 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tuscaloosa", "state": "Alabama" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Palm Desert", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01087788" } ] }